Table 2. Pathologic Axillary Status in 527 Patients With and Without a Breast pCR After NCT.

Breast Cancer Subtype	No. of Nodes With Positive Histologic Finding, No. (%) of Patients
	0	1	2	≥3	All
Breast pCR
HER2+
T1N0	6 (100)	0	0	0	6 (100)
T2N0	46 (100)	0	0	0	46 (100)
T1N1	10 (76.9)	2 (15.4)	1 (7.7)	0	13 (100)
T2N1	27 (93.1)	1 (3.4)	0	1 (3.4)	29 (100)
TN
T1N0	12 (100)	0	0	0	12 (100)
T2N0	52 (100)	0	0	0	52 (100)
T1N1	6 (100)	0	0	0	6 (100)
T2N1	26 (89.7)	2 (6.9)	0	1 (3.4)	29 (100)
HER2+ and TN
T1N0	18 (100)	0	0	0	18 (100)
T2N0	98 (100)	0	0	0	98 (100)
T1N1	16 (84.2)	2 (10.5)	1 (5.3)	0	19 (100)
T2N1	53 (91.4)	3 (5.2)	0	2 (3.4)	58 (100)
No Breast pCR
HER2+
T1N0	8 (100)	0	0	0	8 (100)
T2N0	71 (98.6)	1 (1.4)	0	0	72 (100)
T1N1	10 (71.4)	1 (7.1)	1 (7.1)	2 (14.3)	14 (100)
T2N1	36 (48.0)	7 (9.3)	16 (21.3)	16 (21.3)	75 (100)
TN
T1N0	6 (85.7)	1 (14.3)	0	0	7 (100)
T2N0	79 (90.8)	8 (9.2)	0	0	87 (100)
T1N1	3 (33.3)	0	3 (33.3)	3 (33.3)	9 (100)
T2N1	19 (30.6)	4 (6.5)	16 (25.8)	23 (37.1)	62 (100)
HER2+ and TN
T1N0	14 (93.3)	1 (6.7)	0	0	15 (100)
T2N0	150 (94.3)	9 (5.7)	0	0	159 (100)
T1N1	13 (56.5)	1 (4.3)	4 (17.4)	5 (21.7)	23 (100)
T2N1	55 (40.1)	11 (8.0)	32 (23.4)	39 (28.5)	137 (100)

Abbreviations: NCT, neoadjuvant chemotherapy; pCR, pathologic complete response; TN, triple-negative; +, positive.